Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

uniQure N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

~ U.S. AND U.K. REGULATORY SUBMISSIONS FOR AMT-130 FOR HUNTINGTON'S DISEASE ON TRACK AS PLANNED FOR THE THIRD QUARTER OF 2026 ~ ~ TOPLINE FOUR-YEAR DATA FROM THE PHASE I/II STUDY OF AMT-130 EXPECTED IN SEPTEMBER 2026 ~ ~ REPORTED DATA FROM THE FIRST COHORT IN THE PHASE I/IIA TRIAL OF AMT-260 FOR REFRACTORY MESIAL TEMPORAL LOBE EPILEPSY SHOWED EARLY BIOLOGICAL SIGNALS OF THERAPEUTIC ACTIVITY AND A FAVORABLE SAFETY PROFILE ~ ~ STRENGTHENED FINANCIAL POSITION WITH $259 MILLION FOLLOW-ON OFFERING, EXTENDING CASH RUNWAY INTO 2030 AND FUNDING THE ANTICIPATED COMMERCIAL LAUNCH OF AMT-130 AND CONTINUED PIPELINE INVESTMENT ~ ~ UNIQURE TO HOST EARNINGS CALL AT 8:30 A.M. ET ~ LEXINGTON, MASS.

UNIQURE ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES COMPANY UPDATE

~ UNIQURE TO HOST EARNINGS CALL ON WEDNESDAY, JULY 29, 2026 AT 8:30 A.M. ET ~ ~ UNIQURE TO HOST EARNINGS CALL ON WEDNESDAY, JULY 29, 2026 AT 8:30 A.M. ET ~

UNIQURE TO ANNOUNCE SECOND QUARTER 2026 FINANCIAL RESULTS

LEXINGTON, MASS. AND AMSTERDAM, JUNE 25, 2026 (GLOBE NEWSWIRE) -- UNIQURE N.V. (NASDAQ: QURE), A LEADING GENE THERAPY COMPANY ADVANCING TRANSFORMATIVE THERAPIES FOR PATIENTS WITH SEVERE MEDICAL NEEDS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 5,686,813 ORDINARY SHARES AT A PUBLIC OFFERING PRICE OF $45.50 PER SHARE, WHICH INCLUDES 741,758 ORDINARY SHARES ISSUED PURSUANT TO THE EXERCISE IN FULL BY THE UNDERWRITERS OF THEIR OPTION TO PURCHASE ADDITIONAL ORDINARY SHARES IN THE OFFERING. THE AGGREGATE GROSS PROCEEDS TO UNIQURE FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY UNIQURE, WERE APPROXIMATELY $259 MILLION. ALL SECURITIES IN THE OFFERING WERE SOLD BY UNIQURE.

UNIQURE ANNOUNCES CLOSING OF UPSIZED PUBLIC OFFERING AND FULL EXERCISE BY UNDERWRITERS OF OPTION TO PURCHASE ADDITIONAL SHARES

LEXINGTON, MASS. AND AMSTERDAM, JUNE 23, 2026 (GLOBE NEWSWIRE) -- UNIQURE N.V. (NASDAQ: QURE), A LEADING GENE THERAPY COMPANY ADVANCING TRANSFORMATIVE THERAPIES FOR PATIENTS WITH SEVERE MEDICAL NEEDS, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 4,945,055 ORDINARY SHARES AT A PUBLIC OFFERING PRICE OF $45.50 PER SHARE. THE AGGREGATE GROSS PROCEEDS TO UNIQURE FROM THE OFFERING, BEFORE DEDUCTING THE UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES PAYABLE BY UNIQURE, ARE EXPECTED TO BE APPROXIMATELY $225 MILLION. ALL SECURITIES TO BE SOLD IN THE OFFERING ARE BEING SOLD BY UNIQURE. IN ADDITION, UNIQURE HAS GRANTED TO THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO 741,758 ADDITIONAL ORDINARY SHARES AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT JUNE 25, 2026, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

UNIQURE ANNOUNCES PRICING OF UPSIZED $225 MILLION PUBLIC OFFERING

LEXINGTON, MASS. AND AMSTERDAM, JUNE 22, 2026 (GLOBE NEWSWIRE) -- UNIQURE N.V. (NASDAQ: QURE), A LEADING GENE THERAPY COMPANY ADVANCING TRANSFORMATIVE THERAPIES FOR PATIENTS WITH SEVERE MEDICAL NEEDS, TODAY ANNOUNCED THAT IT HAS COMMENCED A $150 MILLION UNDERWRITTEN PUBLIC OFFERING OF ITS ORDINARY SHARES AND, IN LIEU OF ORDINARY SHARES TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE ITS ORDINARY SHARES. ALL SECURITIES TO BE SOLD IN THE OFFERING WILL BE OFFERED BY UNIQURE. IN ADDITION, UNIQURE INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $22.5 MILLION OF ITS ORDINARY SHARES ON THE SAME TERMS AND CONDITIONS. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

UNIQURE ANNOUNCES $150 MILLION PROPOSED PUBLIC OFFERING

~ AMT-260 WAS GENERALLY WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS OBSERVED TO DATE, WITH EARLY BIOLOGICAL SIGNALS OF POTENTIAL THERAPEUTIC ACTIVITY ~

UNIQURE ANNOUNCES PRELIMINARY DATA ON THE FIRST COHORT IN THE PHASE I/IIA CLINICAL TRIAL OF AMT-260 IN REFRACTORY MESIAL TEMPORAL LOBE EPILEPSY

~ 3-YEAR ANALYSIS FROM THE PHASE I/II STUDY CAN SERVE AS THE PRIMARY BASIS OF A BIOLOGICS LICENSE APPLICATION FOR ACCELERATED APPROVAL WITH FDA ~

UNIQURE ANNOUNCES PLAN FOR BLA SUBMISSION FOR AMT-130 IN HUNTINGTON'S DISEASE

~ ADVANCING FDA INTERACTIONS ON AMT-130 FOR HUNTINGTON'S DISEASE; TYPE B MEETING SCHEDULED FOR THE SECOND QUARTER OF 2026 ~

UNIQURE ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES RECENT COMPANY UPDATES

~ SUBMISSION OF A UK MARKETING AUTHORIZATION APPLICATION FOR AMT-130 IS EXPECTED IN THE THIRD QUARTER OF 2026 ~

UNIQURE ANNOUNCES SUCCESSFUL UK MHRA PRE-SUBMISSION MEETING FOR AMT-130 IN HUNTINGTON'S DISEASE

~ UNIQURE TO HOST EARNINGS CALL ON TUESDAY, MAY 5, 2026 AT 8:30 A.M. ET ~ LEXINGTON, MASS.

uniQure N.V.

QURE

Price

Financial Reports

No items found.

Press Releases

uniQure N.V.

QURE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

QURE